Skip to Main Content

Paper Details

A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
Clin Cancer Res
3
2022
Everolimus, HNSCC, Locally Advanced Squamous Cell Cancer of the Head and Neck, Patients, TP53, TP53mut, advanced-stage HNSCC, advanced-stage head and neck squamous cell carcinoma, everolimus, human, human papillomavirus, mTOR, men, p16, patients, women
Author NameAffiliation
David Neil HayesUniversity of Tennessee Health Science Center
David Neil HayesUniversity of Tennessee Health Science Center
Olivier HarismendyMoores Cancer Center, University of California San Diego
Jorge Silvio GutkindMoores Cancer Center, University of California San Diego
Ezra E W CohenThe University of Chicago
  • 1 - 5

Datasets

Release 1.2